Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor
Takeshi Fukuda(Jikei University School of Medicine), Naoki Tanaka(Kyushu University), Y. Kawabata(Daiichi-Sankyo (Japan)), Ken J. Ishii(The University of Tokyo), Shinichi Takahashi(Daiichi-Sankyo (Japan)), Daichi Baba(Yokohama City University), Shuichiro Ito(Daiichi-Sankyo (Japan)), Tatsuya Nishi(Okayama University), Kyoji Yamaguchi(Daiichi-Sankyo (Japan)), Takashi Ishiyama(Daiichi-Sankyo (Japan)), Riko Kitazawa(Ehime University Hospital)
Cited by 0
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
|Biochemical and Biophysical Research Communications|1998|746
Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell Cultures
|Biochemical and Biophysical Research Communications|1998|344